Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How can keytruda's side effects be managed during breast cancer therapy?Can Viread be used for both HIV and Hep B?Is Synagis still used for RSV?How does Fruquintinib treat cancer?Pomalyst patent expiration?
See the DrugPatentWatch profile for Viread
What conditions can Viread treat? Viread, also known as tenofovir disoproxil fumarate (TDF), is an antiviral medication primarily used to treat HIV-1 infection and chronic hepatitis B virus (HBV) infection [1]. It works by inhibiting the replication of these viruses. How does Viread compare with other HIV treatments? Compared to some other HIV treatments, Viread has a more favorable resistance profile, making it a favorable option for treatment-experienced patients [2]. However, its effectiveness when used in combination with other medications can vary depending on the individual's HIV strain and treatment history. What is the recommended dosage for Viread in HIV and Hep B treatment? For HIV treatment, the recommended dosage of Viread is 300 mg once daily, taken in combination with other antiretroviral medications. For chronic Hep B infection, the recommended dosage is the same, 300 mg once daily, often taken in combination with other antiviral medications [3]. Can Viread cause side effects? Common side effects of Viread include nausea, diarrhea, and kidney problems. In rare cases, it may cause bone density loss, kidney impairment, or increased risk of osteoporosis. Regular monitoring of liver function and bone health is crucial when using Viread [4]. What are the patent and exclusivity details for Viread? Tenofovir disoproxil fumarate (Viread) is developed by Gilead Sciences. The U.S. patent for Viread expired in April 2022. The exclusivity for the HIV indication expired in 2020, while the exclusivity for the Hep B indication expired in 2019 according to DrugPatentWatch.com [5]. Sources: [1] Gilead Sciences. (n.d.). VIREAD (tenofovir disoproxil fumarate) Tablets. [2] Thompson MA, et al. (2018). Antiretroviral Therapy and Medical Management of Pediatric HIV Infection: Recommendations from the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases, 66(6), 865–887. [3] Gilead Sciences. (n.d.). HEART-G (Hepatitis B Research in Adults to Explore the Role of Tenofivir Disoproxil Fumarate). [4] Gilead Sciences. (n.d.). VIREAD (tenofovir disoproxil fumarate) Tablets Package Insert. [5] DrugPatentWatch.com. (n.d.). Viread Patent Expiration Date.